CommentaryEuropean Policy

Translational Medicine Policy Issues in Infectious Disease

See allHide authors and affiliations

Science Translational Medicine  13 Jan 2010:
Vol. 2, Issue 14, pp. 14cm2
DOI: 10.1126/scitranslmed.3000375

Figures

  • Fig. 1. Death by infection.

    Viral and bacterial infections are responsible for a large fraction of deaths worldwide. This digitally colorized negative-stained transmission electron micrograph shows several influenza A virions.

    CREDIT: F. A. MURPHY/CENTERS FOR DISEASE CONTROL AND PREVENTION

Tables

  • Table 1. European institutions with responsibility for developing and applying policy associated with translational medicine.

    Activities at the EU level must also take into account the role of national authorities to support research, deliver public health, and manage the approval and availability of medical products.

    InstitutionDescription
    European CommissionDirectorates-General for Research, Enterprise, and Public Health have operational roles to support health-related research and its application. The European Commission initiates law-making, develops policies, and manages programs while respecting the principle of subsidiarity (in those domains where the EU does not have exclusive competence to act).
    European AgenciesECDC has roles to identify, assess, and communicate threats from infection. EMEA has responsibility for EU-wide marketing authorization, comprising assessment, supervision, and pharmacovigilance.
    European ParliamentDirectly elected body of EU that can draft legislation and request the executive to present proposals. Has codecision role in law-making with EU Council.
    Council of EUComposed of ministers from member states and has codecision role with Parliament. Can also set out general guidelines and political priorities for the other institutions. Presidency of the council is held by each member state for 6 months in turn under a rotating system.

Stay Connected to Science Translational Medicine

Navigate This Article